Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
AUANewsWorthy Webinars
In collaboration with industry leaders, we are proud to present a series of thought-provoking webinars designed to empower professionals in what's new in the field of urology. Whether you’re a practice manager, resident, young urologist, or a seasoned urologist, these webinars offer a unique opportunity to explore the latest topics, strategies, and advancements shaping urology today.
Upcoming Webinar
Prostate Cancer Risk Stratification: Utilizing IsoPSA with mpMRI
November 20, 2025 | 3:30 p.m. ET
Join Urologic Oncologist Dr. Tarik Benidir for an in-depth presentation on how IsoPSA and mpMRI can complement each other to improve prostate biopsy decision making. This session will review clinical evidence on combining IsoPSA results with PI-RADS scoring.
On-Demand Webinars
October 2025
In this webinar, attendees will learn how advanced imaging with 68Gallium PSMA 11 enhances clinical decision-making in prostate cancer. Attendees will also examine diagnostic PET/CT in renal cancer utilizing 89Zr-girentuximab as evidenced by the ZIRCON study.
September 2025
This presentation on INLEXZO™, (gemcitabine intravesical system) will focus on efficacy, safety information, and procedural education.
August 2025
As with any diagnostic modality, there can be challenges associated with understanding the clinical utility of advanced imaging. Telix Physician Education & Engagement is pleased to offer this educational program focused on 68Ga-PSMA-11 for PET/CT imaging of Prostate Cancer.
July 2025
Efficiency is key to better outcomes for patients and providers. By applying the right technology across key areas—or “efficiency levers”—forward-thinking practices are achieving real operational efficiency, scaling revenue, and driving sustainable growth. In this session we’ll explore how AI and automation are helping urology practices transform core areas like revenue cycle, staffing, patient access, clinical documentation, and more. Walk away with real-world strategies to improve performance now and scale for the future.
June 2025
This webinar unveils new second generation CVAC System data from AUA and EAU 2025, highlighting intrarenal pressure (IRP), real-world outcomes, and comparisons vs. DISS and FANS. Learn how Calyxo’s all-in-one aspiration system—integrating ureteroscopy, lithotripsy, irrigation, and aspiration—enables low IRP and improved stone clearance. Explore clinical findings, real-world cases, and the role of aspiration in achieving stone-free outcomes.
May 2025
The standard treatment for muscle-invasive urothelial carcinoma (MIUC) has been radical surgery combined with cisplatin-based chemotherapy for eligible patients. However, over 50% of patients face metastatic progression after surgery. This non-CME webinar, presented by a urology expert, will discuss how patients with UC at high risk of recurrence after radical resection may benefit from adjuvant immunotherapy, emphasize the role of multidisciplinary communication in patient care, and review a subcutaneous immunotherapy option for the adjuvant treatment of UC.
February 2025
Join Michael Johnson, MD, FACS, and David Morris, MD, FACS, as they discuss the value of real-world evidence and how it can be incorporated into daily practice to support shared decision-making. This webinar will delve into key data from 2 recent head-to-head real-world analyses of androgen receptor pathway inhibitors to explore survival outcomes in metastatic castration-sensitive prostate cancer.
November 2024
A discussion on the role of a novel treatment in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). We will consider the challenges of treating BCG-unresponsive high-risk NMIBC, understand the durability, dosing, and safety profile, as well as review practical considerations for incorporating novel treatment into your clinic.
